{{Expand English
| 1=Linezolid
| date=2016-05-16
| fa=yes
| topic=药理学
}}
{{medical}}
{{drugbox
| Verifiedfields = changed
| verifiedrevid = 415028406
| IUPAC_name = (''S'')-''N''-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
| image = Linezolid.svg
| alt = 利奈唑胺的结构式

| image2 = Linezolid-from-xtal-2008-3D-balls.png

<!--Clinical data-->
| tradename = Zyvox, Zyvoxam, Zyvoxid <!-- not all the generics here, please! -->
| Drugs.com = {{drugs.com|monograph|linezolid}}
| MedlinePlus = a602004
| licence_US = Linezolid
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 静脉注射，口服

<!--Pharmacokinetic data-->
| bioavailability = ~100% (口服)
| protein_bound = 低 (31%)
| metabolism = [[肝脏|经肝]] (50–70%, [[细胞色素P450|CYP]] not 参与)
| elimination_half-life = 4.2–5.4 h (儿童更短)
| excretion = 非肾, [[肾|尿液]], 粪便

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 165800-03-3
| ATC_prefix = J01
| ATC_suffix = XX08
| PubChem = 441401
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00601
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 390139
| NIAID_ChemDB = 070944
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ISQ9I6J12J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00947
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 126

<!--Chemical data-->
| C=16 | H=20 | F=1 | N=3 | O=4 
| molecular_weight = 337.346 g/mol
| smiles = O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
| InChI = 1/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TYZROVQLWOKYKF-ZDUSSCGKSA-N
}}

'''利奈唑胺'''（{{lang|en|Linezolid}}）为一种人工合成的唑烷酮类[[抗细菌药|抗细菌药]]，由Pharmacia和Upjohn公司开发，用于治疗对其它几种抗生素有抗性的[[革兰氏阳性菌|革兰氏阳性菌]]所造成的严重[[感染|感染]]。利奈唑胺对大多数引起疾病的革兰氏阳性细菌具有活性，包括[[链球菌|链球菌]]，[[抗萬古黴素腸球菌|耐万古霉素肠球菌]]（VRE）和[[耐甲氧西林金黄色葡萄球菌|耐甲氧西林金黄色葡萄球菌]]（MRSA）。用于治疗皮肤感染与肺炎，不过可能可以用于其他感染，如耐药结核病。使用方法为口服或静脉注射。

==医疗用途==
===皮肤和软组织感染===
===肺炎===
===其他===
====中枢神经系统感染====
====尿路感染====
==禁忌症==
　　腎臟扮演了清除Linezolid及其主要代謝物的重要角色，在腎臟受損的患者血液中Linezolid及其主要代謝物的濃度明顯比腎臟未受損的患者來的高<ref>{{cite journal |author1=Souza |coauthors=E., Crass, R. L., Felton, J., Hanaya, K., & Pai, M. P. |title=Accumulation of major linezolid metabolites in patients with renal impairment. |journal=Antimicrobial Agents and Chemotherapy |date=2020 |volume=64(5) |pmid=32152085}}</ref>，目前市場上的Linezolid藥物標示有註記：「由於Linezolid藥物的初級代謝物之累積缺乏臨床上的數據，腎臟功能缺乏的患者應被注意其使用的潛在風險。」


{{蛋白质合成抑制剂类抗生素}}

[[Category:抗生素|Category:抗生素]]
[[Category:輝瑞產品|Category:輝瑞產品]]
[[Category:肝毒素|Category:肝毒素]]